← Leaderboards
Jun Tan
University Of South Florida
$8,814,686
Attributed
$10,283,007
Total exposure
15
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–19$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$10,283,007 · 13
VA$0 · 2
By mechanism
R01$4,721,527 · 4
R42$2,592,620 · 1
R21$1,628,163 · 4
P01$856,291 · 1
R43$344,023 · 2
R41$140,383 · 1
Top collaborators
- William V. Nikolic3 shared
- Cyndy Davis Sanberg3 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposBrainIn VivoProductionSignal TransductionMouse ModelS DiseaseIn VitroInflammatoryCytokinePathologyCellsTnfrsf5 GeneDepositionPeptidesResponsePhenotypeAmyloidAnti-InflammatorySignal PathwayCerebrumMicrogliaFutureMediating
Grant awards (43)
LISPRO, an ionic cocrystal of lithium, as a potential novel treatment for Alzheimer's disease$373,750
R01 · FY2019 · AG · contact PI
LISPRO, an ionic cocrystal of lithium, as a potential novel treatment for Alzheimer's disease$373,750
R01 · FY2018 · AG · contact PI
Identification of novel APP-specific alpha secretase in human umbilical cord blood sera$186,875
R21 · FY2018 · AG · contact PI
LISPRO, an ionic cocrystal of lithium, as a potential novel treatment for Alzheimer's disease$373,750
R01 · FY2017 · AG · contact PI
Identification of novel APP-specific alpha secretase in human umbilical cord blood sera$224,250
R21 · FY2017 · AG · contact PI
LISPRO, an ionic cocrystal of lithium, as a potential novel treatment for Alzheimer's disease$373,750
R01 · FY2016 · AG · contact PI
A flavonoid gamma-secretase modulator (GSM) reduces beta-amyloid and tau pathologies in the AD mice$186,875
R21 · FY2016 · AG · contact PI
Octyl gallate (OG) and Promotion of non-amyloidogenic processing of APP$0
I01 · FY2016 · VA · contact PI
Flavonoid-diosmin modulation of Abeta and tau pathologies through GSK-3 signaling$326,283
R01 · FY2015 · AT · contact PI
A flavonoid gamma-secretase modulator (GSM) reduces beta-amyloid and tau pathologies in the AD mice$224,250
R21 · FY2015 · AG · contact PI
Octyl gallate (OG) and Promotion of non-amyloidogenic processing of APP$0
I01 · FY2015 · VA · contact PI
Flavonoid-diosmin modulation of Abeta and tau pathologies through GSK-3 signaling$336,375
R01 · FY2014 · AT · contact PI
Octyl gallate (OG) and Promotion of non-amyloidogenic processing of APP$0
I01 · FY2014 · VA · contact PI
Implication of HUCBC: a novel therapeutic strategy for Alzheimer's disease$269,257
R01 · FY2013 · AG · contact PI
Octyl gallate (OG) and Promotion of non-amyloidogenic processing of APP$0
I01 · FY2013 · VA · contact PI
HUCBC modulation of Alzheimer's-like pathology and behavioral changes$802,085
R42 · FY2012 · AG · contact PI
Implication of HUCBC: a novel therapeutic strategy for Alzheimer's disease$284,928
R01 · FY2012 · AG · contact PI
Statin modulation of immunotherapy for Alzheimer disease$0
I01 · FY2012 · VA · contact PI
HUCBC modulation of Alzheimer's-like pathology and behavioral changes$1,569,916
R42 · FY2011 · AG · contact PI
Implication of HUCBC: a novel therapeutic strategy for Alzheimer's disease$284,928
R01 · FY2011 · AG · contact PI
IL-6-mediated Jak2/Stat3 signaling and Brain Development$181,913
R21 · FY2011 · MH · contact PI
Statin modulation of immunotherapy for Alzheimer disease$0
I01 · FY2011 · VA · contact PI
Implication of HUCBC: a novel therapeutic strategy for Alzheimer's disease$296,429
R01 · FY2010 · AG · contact PI
HUCBC modulation of Alzheimer's-like pathology and behavioral changes$220,619
R42 · FY2010 · AG · contact PI
IL-6-mediated Jak2/Stat3 signaling and Brain Development$220,500
R21 · FY2010 · MH · contact PI
PROJECT 2$169,198
P01 · FY2010 · AG · contact PI
Implication of HUCBC: a novel therapeutic strategy for Alzheimer's disease$299,423
R01 · FY2009 · AG · contact PI
PROJECT 2$165,948
P01 · FY2009 · AG · contact PI
DiosMemTM, a natural gamma-secretase inhibitor, opposes AD pathogenesis$165,254
R43 · FY2009 · AG · contact PI
Oral administration of TeaMemTM inhibits Alzheimer's disease pathogenesis$71,782
R43 · FY2009 · AT · contact PI
Statin modulation of immunotherapy for Alzheimer disease$0
I01 · FY2009 · VA · contact PI
Green tea derived EGCG opposes AIDS dementia-like neuronal damage$183,750
R21 · FY2008 · MH · contact PI
PROJECT 2$161,127
P01 · FY2008 · AG · contact PI
Oral administration of TeaMemTM inhibits Alzheimer's disease pathogenesis$106,987
R43 · FY2008 · AT · contact PI
CD40 Modulation of Abeta-Vaccine Immune Response$281,829
R01 · FY2007 · NS · contact PI
Green tea derived EGCG opposes AIDS dementia-like neuronal damage$219,750
R21 · FY2007 · MH · contact PI
PROJECT 2$188,273
P01 · FY2007 · AG · contact PI
HUCBC modulation of Alzheimer-like pathology and behavioral changes$140,383
R41 · FY2007 · AG · contact PI
CD40 Modulation of Abeta-Vaccine Immune Response$304,410
R01 · FY2006 · NS · contact PI
PROJECT 2$171,745
P01 · FY2006 · AG · contact PI
CD40 Modulation of Abeta-Vaccine Immune Response$14,490
R01 · FY2006 · NS · contact PI
CD40 Modulation of Abeta-Vaccine Immune Response$268,250
R01 · FY2005 · NS
CD40 Modulation of Abeta-Vaccine Immune Response$259,925
R01 · FY2004 · NS